Raju Khk, Jambulingam P, Sabesan S, Vanamail P
Vector Control Research Centre, Indian Council of Medical Research, Indira Nagar, Puducherry - 605 006, India.
J Postgrad Med. 2010 Jul-Sep;56(3):232-8. doi: 10.4103/0022-3859.68650.
Lymphatic filariasis caused by Wuchereria bancrofti and Brugia malayi is an important public health problem in India. Both parasites produce essentially similar clinical presentations in man, related mainly to the pathology of the lymphatic system. Filariasis is endemic in 17 States and six Union Territories, with about 553 million people at risk of infection. The Government of India has accorded a high priority for elimination of this infection through mass chemotherapy programme (annual, single dose of Diethylcarbamazine citrate, i.e. DEC - 6 mg/kg of bodyweight, plus Albendazole repeated four to six times). This campaign has become a part of the National Vector-Borne Disease Control Programme in 2003 under the National Health Policy 2002 and aims to eliminate filariasis by 2015. We discuss here the epidemiology and current control strategy for filariasis; highlighting key issues, challenges and options in the implementation of the programme, and suggesting measures for mid-course corrections in the elimination strategy.
由班氏吴策线虫和马来布鲁线虫引起的淋巴丝虫病是印度一个重要的公共卫生问题。这两种寄生虫在人体产生的临床表现基本相似,主要与淋巴系统的病理学有关。丝虫病在印度17个邦和6个中央直辖区呈地方性流行,约有5.53亿人有感染风险。印度政府高度重视通过大规模化疗计划(每年单剂量服用枸橼酸乙胺嗪,即DEC——6毫克/千克体重,加阿苯达唑重复服用4至6次)来消除这种感染。根据2002年《国家卫生政策》,这项运动在2003年已成为国家病媒传播疾病控制计划的一部分,目标是到2015年消除丝虫病。我们在此讨论丝虫病的流行病学和当前控制策略;强调该计划实施过程中的关键问题、挑战和选择,并提出消除策略中期调整的措施。